Aging may have an effect on the pharmacokinetics (PK) of antiretroviral drugs and hence contribute to differences in efficacy and toxicity. We evaluated the impact of age on the pharmacokinetics of boosted atazanavir in a Thai HIV-1 infected population.
Purpose of the study
Aging may have an effect on the pharmacokinetics (PK) of antiretroviral drugs and hence contribute to differences in efficacy and toxicity. We evaluated the impact of age on the pharmacokinetics of boosted atazanavir in a Thai HIV-1 infected population.
Methods
HIV-infected adults (viral load < 50) on atazanavir/ritonavir 300/100 mg once-daily plus two NRTIs for at least 2 weeks were enrolled. Two 24-hour intensive PK were studied at baseline and 14 days after switching to atazanavir/ ritonavir 200/100 mg once-daily regimen plus two NRTIs. Atazanavir plasma concentrations were calculated using non-compartmental methods. A repeated measures GEE/ random effect model was used to compare the two dose levels. Comparison between the different subgroups were made using the Mann-Whitney U model.
Summary of results
There were 22 patients (11 males, 11 age> 42 yrs, seven tenofovir use, median BW = 59 kg). Females had a significantly lower BMI and BW; other demographics were similar. Women had greater atazanavir exposure compared to men with a median AUC of 70. ; 91% of older group compared to 36% of younger (p = 0.009) had atazanavir Ctrough above 0.85 mg/L. There was an association between lower weight and higher AUC0-24 as well. In multivariate analysis, weight and gender were no longer significant predictors of AUC0-24. Only age was highly significantly associated with AUC0-24 (p =< 0.001), Cmax (p =< 0.001), Ctrough (p = 0.012), and clearance (p = 0.002). However, body weight was associated with Cmax (p = 0.006). There was no significant relationship between half-life and gender, weight, age, whether the patient was using TDF or the AUC0-24 of RTV.
Conclusion
Older patients appear to have different PK profiles for atazanavir in our population. Large trials are warranted to confirm this result.
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